Tharimmune Inc (THAR)

Apr 02, 2025

Virtu Financial LLC Makes New Investment in Tharimmune, Inc. (NASDAQ:THAR) - Defense World

Apr 02, 2025

Mar 31, 2025

THAR stock touches 52-week low at $1.2 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 31, 2025

Jayud Global Logistics Ltd (JYD): What Makes The Stock Good? - Marketing Sentinel

Mar 31, 2025

Mar 31, 2025

THAR stock touches 52-week low at $1.2 amid sharp annual decline - Investing.com

Mar 31, 2025

Mar 31, 2025

Tharimmune Says FDA Requires No Additional Trials of TH104 Against Opioid Exposure - MarketScreener

Mar 31, 2025

Mar 31, 2025

FDA greenlights Tharimmune’s drug application pathway - Investing.com India

Mar 31, 2025

Mar 31, 2025

Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure - Weatherford Democrat

Mar 31, 2025

Mar 31, 2025

FDA Fast-Tracks Tharimmune's Revolutionary Opioid Defense Drug: No Clinical Trials Needed - Stock Titan

Mar 31, 2025

Mar 24, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Mar 24, 2025

Mar 24, 2025

Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha - Weatherford Democrat

Mar 24, 2025

Mar 24, 2025

Game-Changing Oral Alternative to Injectable Antibody Achieves Key Milestone - Stock Titan

Mar 24, 2025

Mar 05, 2025

Tharimmune leverages Epiclick platform to expand pipeline - BioWorld Online

Mar 05, 2025

Mar 04, 2025

Hillstream Biopharma stock hits 52-week low at $1.36 - Investing.com

Mar 04, 2025

Mar 04, 2025

Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology - Markets Insider

Mar 04, 2025

Mar 04, 2025

Tharimmune unveils novel cancer treatment HS1940 - Investing.com India

Mar 04, 2025

Mar 04, 2025

Tharimmune unveils novel cancer treatment HS1940 By Investing.com - Investing.com South Africa

Mar 04, 2025

Mar 01, 2025

Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Declines By 58.6% - Defense World

Mar 01, 2025

Mar 01, 2025

Short Interest in Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Expands By 148.7% - Defense World

Mar 01, 2025

Feb 27, 2025

Tharimmune appoints new CFO following resignation By Investing.com - Investing.com Canada

Feb 27, 2025

Feb 27, 2025

Tharimmune Says Thomas Hess Resigns As CFO -February 27, 2025 at 05:34 pm EST - Marketscreener.com

Feb 27, 2025

Feb 27, 2025

Tharimmune Says Thomas Hess Resigns As CFO - TradingView

Feb 27, 2025

Feb 27, 2025

Tharimmune appoints new CFO following resignation - Investing.com

Feb 27, 2025

Feb 25, 2025

Hillstream Biopharma stock hits 52-week low at $1.83 By Investing.com - Investing.com Canada

Feb 25, 2025

Feb 24, 2025

Hillstream Biopharma stock hits 52-week low at $1.83 - Investing.com

Feb 24, 2025

Feb 23, 2025

Financial Analysis: ObsEva (NASDAQ:OBSV) & Tharimmune (NASDAQ:THAR) - Defense World

Feb 23, 2025

Feb 22, 2025

Comparing Tharimmune (NASDAQ:THAR) and Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World

Feb 22, 2025

Feb 19, 2025

Tharimmune (NASDAQ:THAR) and Cara Therapeutics (NASDAQ:CARA) Head-To-Head Review - Armenian Reporter

Feb 19, 2025

Feb 17, 2025

Comparing Cara Therapeutics (NASDAQ:CARA) & Tharimmune (NASDAQ:THAR) - Defense World

Feb 17, 2025

Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Communications

Feb 13, 2025

Feb 07, 2025

Tharimmune (NASDAQ:THAR) Trading 3% Higher – Should You Buy? - Defense World

Feb 07, 2025

Jan 27, 2025

Tharimmune to Present at the Microcap Conference 2025 - Bellingham Herald

Jan 27, 2025

Jan 27, 2025

Tharimmune to Present at Microcap Conference 2025, Showcase Growth Strategy - StockTitan

Jan 27, 2025

Jan 25, 2025

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - ACCESS Newswire

Jan 25, 2025

Jan 25, 2025

Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis - ACCESS Newswire

Jan 25, 2025

Jan 25, 2025

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - ACCESS Newswire

Jan 25, 2025

Dec 21, 2024

tharimmune CEO Randy Milby buys shares worth $9,752 - Investing.com India

Dec 21, 2024

Dec 20, 2024

tharimmune CEO Randy Milby buys shares worth $9,752 By Investing.com - Investing.com Canada

Dec 20, 2024

Dec 20, 2024

Tharimmune files to sell 1.44 million shares of common stock by selling shareholders - MSN

Dec 20, 2024

Dec 16, 2024

Tharimmune, Inc. Appoints Sanam Parikh to Its Board of Directors - Marketscreener.com

Dec 16, 2024

Dec 16, 2024

Tharimmune plans Phase 2 trial for itch treatment TH104 - Investing.com

Dec 16, 2024

Dec 16, 2024

Tharimmune plans Phase 2 trial for itch treatment TH104 By Investing.com - Investing.com UK

Dec 16, 2024

Dec 16, 2024

Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update - Eagle-Tribune

Dec 16, 2024

Dec 16, 2024

Tharimmune Advances TH104 Clinical Program: Phase 2 Trial Set for 2025 After Positive Phase 1 Results - StockTitan

Dec 16, 2024

Dec 14, 2024

U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.55% - MSN

Dec 14, 2024

Dec 11, 2024

Tharimmune announces $2.02M private placement; shares up - MSN

Dec 11, 2024

Dec 08, 2024

Tharimmune (NASDAQ:THAR) Coverage Initiated at Rodman & Renshaw - Defense World

Dec 08, 2024

Dec 07, 2024

Rodman & Renshaw Initiates Coverage of Tharimmune (THAR) with Buy Recommendation - MSN

Dec 07, 2024

Dec 07, 2024

Tharimmune secures $2.02 million in private funding By Investing.com - Investing.com Nigeria

Dec 07, 2024